Zimmer Biomet Enters Material Definitive Agreement
Ticker: ZBH · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1136869
Sentiment: neutral
Topics: debt, financing, agreement
Related Tickers: ZBH
TL;DR
ZBH inked a deal on its 2026 & 2027 notes, filing financials too.
AI Summary
On November 13, 2024, Zimmer Biomet Holdings, Inc. entered into a material definitive agreement related to its M2.425 Notes due 2026 and M1.164 Notes due 2027. The company also filed financial statements and exhibits as part of this report.
Why It Matters
This filing indicates a significant financial transaction or agreement for Zimmer Biomet, potentially impacting its debt structure and future financial obligations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new financial obligations or strategic shifts that carry inherent risks.
Key Numbers
- 2026 — M2.425 Notes Maturity Year (Indicates a specific debt maturity)
- 2027 — M1.164 Notes Maturity Year (Indicates a specific debt maturity)
Key Players & Entities
- ZIMMER BIOMET HOLDINGS, INC. (company) — Registrant
- November 13, 2024 (date) — Date of earliest event reported
- M2.425 Notes due 2026 (dollar_amount) — Debt instrument
- M1.164 Notes due 2027 (dollar_amount) — Debt instrument
FAQ
What specific terms are included in the material definitive agreement for the M2.425 Notes due 2026 and M1.164 Notes due 2027?
The filing does not provide specific terms of the agreement, only that a material definitive agreement was entered into.
What is the total principal amount of the M2.425 Notes due 2026 and M1.164 Notes due 2027?
The filing references these notes by their principal amounts (M2.425 and M1.164), but the exact total dollar value is not explicitly stated in this summary.
What is the purpose of entering into this material definitive agreement?
The filing does not state the specific purpose of the agreement.
Are there any immediate financial implications for Zimmer Biomet as a result of this agreement?
The filing indicates a material definitive agreement was entered into, suggesting potential financial implications, but does not detail them.
What financial statements and exhibits were filed along with this 8-K?
The filing states that financial statements and exhibits were filed, but their specific content is not detailed in this summary.
Filing Stats: 1,167 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2024-11-19 16:15:35
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ZBH New York Stock Exchan
- $850.0 million — eir affiliates own any of the Company's $850.0 million outstanding aggregate principal amount
Filing Documents
- d903626d8k.htm (8-K) — 34KB
- d903626dex11.htm (EX-1.1) — 230KB
- 0001193125-24-261733.txt ( ) — 474KB
- zbh-20241113.xsd (EX-101.SCH) — 4KB
- zbh-20241113_def.xml (EX-101.DEF) — 13KB
- zbh-20241113_lab.xml (EX-101.LAB) — 22KB
- zbh-20241113_pre.xml (EX-101.PRE) — 14KB
- d903626d8k_htm.xml (XML) — 7KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 1.1 Underwriting Agreement, dated as of November 13, 2024, among Zimmer Biomet Holdings, Inc., Barclays Bank PLC, Goldman Sachs & Co. LLC, HSBC Bank plc and RBC Europe Limited. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding the closing of the offering of the Notes and the Company's intended use of proceeds. Forward-looking statements may be identified by the use of forward-looking terms such as "intends," "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "sees," "seeks," "should," "could" and similar expressions or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements, including risks that the offering of the Notes is not consummated on the anticipated terms, if at all. For a list and description of some of such risks, uncertainties and changes in circumstances, see the Company's filings with the Securities and Exchange Commission (the "SEC"). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the Company's filings with the SEC. Forward-looking statements speak only as of the date they are ma
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 19, 2024 ZIMMER BIOMET HOLDINGS, INC. By: /s/ Chad F. Phipps Name: Chad F. Phipps Title: Senior Vice President, General Counsel and Secretary